Start here if you're new
what it is
Ligand buys or licenses drug royalty streams and collects cash from other companies' medicines.
how it gets paid
Last year Ligand Pharm made $268M in revenue. royalty-generating assets was the main engine at $0.14B, or 52% of sales.
why it's growing
Revenue grew 60.4% last year. The 81% revenue jump matters most. It says the royalty stream is still climbing fast.
what just happened
Ligand's latest quarter printed $208M of revenue, up 81%, while EPS landed at $3.95.
At a glance
B+ balance sheet — decent shape, but not bulletproof
5/100 earnings predictability — expect surprises
88.8x trailing p/e — you're paying up for this one
7.7% return on capital — nothing to write home about
-$0.22 fy2024 eps est
xvary composite: 54/100 — below average
What they do
Ligand buys or licenses drug royalty streams and collects cash from other companies' medicines.
Ligand has 68 employees and 9 named pharma partners. That is a skeleton crew collecting checks from Novartis, Amgen, Merck, Pfizer, Gilead, Janssen, Baxter, and Eli Lilly. royalty streams (cash checks from other companies' drugs) beat factories because your lab bill stays small while patented Captisol keeps the door locked.
How they make money
$268M
annual revenue · their business grew +60.4% last year
royalty-generating assets
$0.14B
Captisol platform technology
$0.05B
milestone payments
$0.04B
license fees
$0.02B
other income
$0.01B
The products that matter
collects partner royalties
Royalty Portfolio
$200M–$225M outlook
this is the engine the market cares about. the page points to a 23% compound annual growth rate in royalty receipts from 2025, which is why the valuation still carries a premium.
core driver
funds outside programs
Capital Partnering
$35M commitment
Ligand committed $35M with Medtronic for a royalty on Orchestra's AVIM therapy. that tells you the model keeps buying future cash-flow optionality instead of building a giant in-house sales machine.
future cash flow
sells materials and other revenue
Material Sales & Other
$45M–$60M range
this bucket is smaller and flat, which matters because it leaves the growth story resting on royalties. if royalties slip, there is not a second fast-growing segment here to hide it.
supporting line
Key numbers
$268M
annual revenue
You are buying a $4B company on a $268M base. That is about 15.0x sales.
88.8x
trailing P/E
You pay 88.8 times trailing earnings for a business with FY2024 EPS of -$0.22. The market is not pricing a cheap mistake.
$450M
debt load
Debt equals 10% of capital. That is not fatal, but it limits your room if rates stay ugly.
7.7%
return on capital
The business earns 7.7% on capital. That is the part where the math gets less heroic than the story.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 30 / 100
- long-term debt $450M (10% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for LGND right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Ligand's latest quarter printed $208M of revenue, up 81%, while EPS landed at $3.95.
The revenue line did the heavy lifting. EPS was down 30% vs. prior year, so the quarter looked strong on sales and softer on profit.
$208M
revenue
$3.95
eps
81%
revenue vs. last year
the number that mattered
The 81% revenue jump matters most. It says the royalty stream is still climbing fast, even while EPS fell 30%.
source: EDGAR filing and company earnings report
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
LGND's biggest risk is not "biotech is risky." It is that the stock is already discounting a royalty ramp while the underlying earnings stream still looks lumpy.
med
royalty concentration
Royalty revenue is shown at $200M–$225M while the whole business posted $167M of annual revenue. When one future line item towers over the current base, a few partnered assets are doing a lot of the work.
If those programs underdeliver, the main growth engine slows and the premium multiple stops looking justified.
med
valuation ahead of earnings
88.8x trailing earnings is a steep price for a company with -$0.22 in the recent EPS base and 5/100 earnings predictability. You are being asked to underwrite tomorrow's earnings today.
If profit growth slips while the multiple stays high, the stock has two problems at once: slower fundamentals and less room for forgiveness.
med
thin external validation
There is no verified three-year total return series on the source page and analyst price target data is marked n/a. That does not make the stock bad. It does make independent confirmation harder.
When data is thin, management commentary and a handful of catalysts can move the narrative more than they would in a widely covered large-cap name.
The combined risk picture is simple: a ~$4B stock on $167M of revenue and 88.8x trailing earnings needs the royalty book to scale cleanly. If that ramp gets pushed out, the valuation does not have much cover.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
royalty revenue range
$200M–$225M is the number that matters most. If management starts walking that down, the stock stops being a royalty ramp story and starts being a patience test.
risk
earnings predictability
5/100 is not a rounding error. It is the page telling you quarters can get messy fast.
calendar
next earnings update
Use the next report to check whether revenue growth still tracks the royalty ramp. Last full review: updated feb 27, 2026.
trend
consensus depth
Target data is thin now. If coverage broadens, you get more outside models. If it stays thin, the stock keeps trading on a narrower set of expectations.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak, there is no clean outside consensus to hide behind.
risk profile
volatile
a 30 / 100 price stability score and a $94–$228 52-week range tell you the stock does not move like a slow healthcare utility.
chart momentum
catalyst-driven
this name trades more on partner updates, royalty expectations, and revised models than on smooth technical trends.
earnings predictability
5/100
predictability measures how stable earnings have been. 5/100 means you should expect uneven quarters until the royalty base gets broader.
source: institutional data
Institutional activity
institutional ownership data for LGND is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$184
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive